Pleus Stefan, Schmid Christina, Link Manuela, Zschornack Eva, Klötzer Hans-Martin, Haug Cornelia, Freckmann Guido
Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany.
J Diabetes Sci Technol. 2013 Jul 1;7(4):833-41. doi: 10.1177/193229681300700405.
This study aimed at evaluating and comparing the performance of a new generation of continuous glucose monitoring (CGM) system versus other CGM systems, under daily lifelike conditions.
A total of 10 subjects (7 female) were enrolled in this study. Each subject wore two Dexcom G4™ CGM systems in parallel for the sensor lifetime specified by the manufacturer (7 days) to allow assessment of sensor-to-sensor precision. Capillary blood glucose (BG) measurements were performed at least once per hour during daytime and once at night. Glucose excursions were induced on two occasions. Performance was assessed by calculating the mean absolute relative difference (MARD) between CGM readings and paired capillary BG readings and precision absolute relative difference (PARD), i.e., differences between paired CGM readings.
Overall aggregate MARD was 11.0% (n = 2392). Aggregate MARD for BG <70 mg/dl was 13.7%; for BG between 70 and 180 mg/dl, MARD was 11.4%; and for BG >180 mg/dl, MARD was 8.5%. Aggregate PARD was 7.3%, improving from 11.6% on day 1 to 5.2% on day 7.
The Dexcom G4 CGM system showed good overall MARD compared with results reported for other commercially available CGM systems. In the hypoglycemic range, where CGM performance is often reported to be low, the Dexcom G4 CGM system achieved better MARD than that reported for other CGM systems in the hypoglycemic range. In the hyperglycemic range, the MARD was comparable to that reported for other CGM systems, whereas during induced glucose excursions, the MARD was similar or slightly worse than that reported for other CGM systems. Overall PARD was 7.3%, improving markedly with sensor life time.
本研究旨在评估并比较新一代连续血糖监测(CGM)系统与其他CGM系统在日常生活条件下的性能。
本研究共纳入10名受试者(7名女性)。每位受试者同时佩戴两个德康G4™ CGM系统,佩戴时间为制造商规定的传感器使用寿命(7天),以评估传感器之间的精度。白天每小时至少进行一次毛细血管血糖(BG)测量,夜间进行一次测量。在两个时间段诱导血糖波动。通过计算CGM读数与配对毛细血管BG读数之间的平均绝对相对差异(MARD)以及精度绝对相对差异(PARD)(即配对CGM读数之间的差异)来评估性能。
总体综合MARD为11.0%(n = 2392)。血糖<70 mg/dl时的综合MARD为13.7%;血糖在70至180 mg/dl之间时,MARD为11.4%;血糖>180 mg/dl时,MARD为8.5%。综合PARD为7.3%,从第1天的11.6%改善至第7天的5.2%。
与其他市售CGM系统报告的结果相比,德康G4 CGM系统显示出良好的总体MARD。在通常报告CGM性能较低的低血糖范围内,德康G4 CGM系统的MARD优于其他CGM系统在低血糖范围内报告的结果。在高血糖范围内,MARD与其他CGM系统报告的结果相当,而在诱导血糖波动期间,MARD与其他CGM系统报告的结果相似或略差。总体PARD为7.3%,随传感器使用寿命显著改善。